Adjuvant engineering for cancer immunotherapy: development of a synthetic TLR2 ligand with alternative functions

摘要

We created a new adjuvant based on the structure of macrophage-activating lipopeptide-2 (MALP2), which is a TLR2 ligand identified in Mycoplasma fermentans. Adjuvant engineering, substituting a functional motif for bacterial origin peptide of MALP2, is a novel drug design strategy.